Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.37 |
| ▸ | HPD | P32754 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30474152 | 0.99 | MCHR1 (0.41) | PNMTMCHR1HTR2CHTR2BHTR2A | |
| SCHEMBL29098132 | 0.83 | HTR2C (0.44) | PNMTMCHR1HTR2CHTR2B | |
| SCHEMBL30474084 | 0.81 | MCHR1 (0.42) | PNMTMCHR1HTR2CHTR2BCYP1A2 | |
| SCHEMBL30474313 | 0.81 | MCHR1 (0.40) | PNMTMCHR1HTR2CHTR2BCYP1A2 | |
| SCHEMBL30474195 | 0.81 | MCHR1 (0.45) | MCHR1CYP1A2CYP2C9TBXA2RPTGS1 | |
| SCHEMBL30474096 | 0.80 | MCHR1 (0.39) | PNMTMCHR1HTR2CHTR2BCYP1A2 | |
| SCHEMBL27427814 | 0.80 | MCHR1 (0.39) | PNMTMCHR1HTR2CHTR2BCYP1A2 | |
| SCHEMBL31317926 | 0.75 | HTR2C (0.53) | PNMTMCHR1HTR2CHTR2BHTR2A | |
| SCHEMBL29097861 | 0.75 | HTR2C (0.53) | PNMTMCHR1HTR2CHTR2BHTR2A | |
| SCHEMBL30583851 | 0.74 | HTR6 (0.45) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| EP-4496797-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | Gasherbrum Bio, Inc. (US) | 2025-01-29 | — | — | EP | disclosed |
| EP-4469444-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023179542-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GASHERBRUM BIO , INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109148-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PNMT 2301/4885MCHR1 217/4885HTR2C 152/4885 |
| US-20250206757-A1 | 5,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETES | GLP1R, IAPP, GPR119 | PNMT 1708/4885MCHR1 1905/4885HTR2C 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.